Biotech Startups
9,851 companies tagged Biotech, with their investors and founders.
Keriton offers a software platform for neonatal and pediatric hospital settings that supports safe infant feeding practices, milk management (donor human milk, formula, and parental human milk), and family engagement through features like secure photo sharing, e-journaling, and clinician messaging. It also provides reporting tools for clinical leaders to support operational decisions and quality improvement in NICU workflows.
3 investors
Kimialys is an industrial company specialized in biosensing, providing its proprietary K-One surface chemistry functionalization platform for gold nanoparticles, chips, and electrodes. It serves laboratories developing diagnostics, therapeutics, and bioanalysis applications in drug discovery and diagnostic development.
3 investors
Kingdom Supercultures develops functional health ingredients using natural microbes, aiming to improve consumer health. Its team combines microbiologists, data scientists, and industry professionals working on microbe-based ingredients.
3 investors
Kira Pharmaceuticals develops therapies targeting the complement system for patients with complement-mediated autoimmune and inflammatory diseases across areas including hematology, nephrology, neurology, dermatology and ophthalmology. It uses a proprietary LOGIC drug discovery platform and has a lead asset entering Phase 2 alongside additional pipeline assets.
3 investors
KiraGen Bio develops gene-edited, donor-derived cell therapies designed to resist tumor microenvironment suppression and maintain durable function. Its platform focuses on combining multiple gene edits to produce scalable, allogeneic cell therapy candidates.
3 investors
KnipBio produces JUV, a fermented all-natural feed ingredient added to existing aquaculture feed to improve juvenile survival, stress resilience, and yields for farmed fish and shrimp. It serves aquaculture producers of species including shrimp, salmonids, and marine fishes, shipping its product worldwide.
3 investors
Kobiolabs (κ³ λ°μ΄μ€λ©) develops microbiome-based drugs using its Smartiome platform, which applies AI-driven microbiome multi-omics analysis and a microbial library for drug discovery. The company focuses on immune, metabolic, and brain/neurological diseases, and uses a biofoundry-based microbe drug delivery system (mDDS).
3 investors
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments. The company serves oncologists and patients with cancer seeking advanced therapeutic solutions.
3 investors
Kolibri develops technology to manufacture cells using acoustic waves.
3 investors
Komham develops microbial technology to decompose organic waste and sells biomass recycling systems based on that research. The company operates in the waste treatment and environmental technology sector in Japan.
3 investors
Koralo develops proprietary co-fermented microalgae and mushroom root ingredients that are clinically tested to support gut health, for use in human functional food and beverages as well as animal feed for aquaculture and pets. The company sells these ingredients to food and feed brands to improve digestive health, performance, and longevity.
3 investors
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
3 investors
Krosslinker develops aerogel-based materials for thermal insulation, including cooling paints, composite boards, and silica aerogel powders. Its products target industrial and building applications requiring lightweight, high-performance insulation.
3 investors
Quantum Lens develops a quantum computing and AI platform for drug discovery that simulates molecular behavior at the atomic level to guide the design of novel drug candidates. The platform targets pharmaceutical companies and biotech researchers working on small-molecule drug discovery, particularly for challenging targets like covalent inhibitors, hard-to-drug enzymes, and allosteric binding sites.
3 investors
Kubanda develops innovative healthcare solutions for pets, focusing on pet wellness.
3 investors
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments. It focuses on translating research into therapies for cancer patients.
3 investors
KYNDA is a B2B technology company that uses submerged fungal fermentation to upcycle food and agricultural sidestreams into protein-rich mycelium ingredients. It provides end-to-end support, from cultures to hardware, enabling decentralised on-site fermentation for the food industry.
3 investors
Labforward develops digital software solutions for laboratory workflows and data management, serving research institutions, biotech companies, and regulated environments. The company integrates lab devices, data, and researchers through interconnected products for scientific discovery and compliance.
3 investors
Latent Labs develops generative AI models for protein design and builds biological platforms to validate AI-driven designs. The company works at the intersection of generative AI, engineering, and biology.
3 investors
Latus develops gene therapies based on novel AAV capsid variants matched to optimized routes of administration, aiming to target specific cell types and tissues to lower dose requirements, toxicity, and manufacturing costs. It focuses on treating monogenic diseases affecting the central nervous system and peripheral tissues using computational methods and unbiased capsid screening.
3 investors
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
3 investors
Lavo Life Sciences offers computational molecular simulations to pharmaceutical companies, helping them optimize drug formulations, reduce experimental costs, and accelerate the path to clinical trials and regulatory approval.
3 investors
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.
3 investors
Lembas develops science-backed supplements and functional ingredients focused on weight management. The company combines research in molecular biology and nutrition science to create evidence-based dietary products.
3 investors